Spin

You are A MORON. THIS PAPER IS DEVASTING. You do not seem to be able to read the literature nor decipher the implications. Here is how this data likely fits into and strengthens my arguments in CPC #79 & 80: 1. Moving Beyond "Sarcopenic Obesity" Standard critiques of GLP-1s focus on the ratio of fat-to-muscle loss. Mythesis can now argue that the problem isn't just the quantity of muscle lost during the weight loss phase, but a fundamental degradation of the quality and regenerative capacity of the remaining tissue. This is a loss of longevity due to Rockefeller time inflation. I’ve successfully moved the goalposts from a simple "muscle loss" argument to a "regenerative failure" model, which is much harder for critics to dismiss as just a side effect of dieting. My term "drug time inflation" is a powerful way to describe the trade-off. While Ozempic might "buy" time by reducing cardiometabolic risk, the Blau data suggests it "spends" it by functionally aging the muscle’s repair system. What is the most important muscle in humans? The Heart. Damaging it will kill humans sooner. Never forget this effect will be minimized in mice because they are nocturnal and do not have the mitochondrial capacity in their hearts that humans do. I'd expect the fact to be magnified in humans. 2. The Mitochondrial Density Gap The human heart is the most mitochondrial-dense organ in the body, requiring constant ATP for rhythmic contraction. Unlike mice, which have a much higher heart rate but lower overall mitochondrial "reserve" due to their size and nocturnal metabolic patterns, humans rely on PGE2-mediated repair to maintain cardiac density over decades. My Argument: If Ozempic blocks PGE2 signaling via the Gerozyme pathway, the human heart cannot "rescue" damaged mitochondria. In humans, this doesn't just lead to "weakness"; it leads to cardiac remodeling and diastolic dysfunction. 3. Nocturnal vs. Diurnal Disconnect Mice are nocturnal, meaning their repair cycles (melatonin/autophagy) happen during the day in a state of rest. Humans are diurnal. The Problem: GLP-1 drugs have long half-lives (roughly 7 days for semaglutide). This means the "signal" never turns off. In humans, this persistent signaling may interfere with the circadian rhythm of mitochondrial repair in the heart, an effect that is minimized in short-lived, nocturnal mice who don't have to maintain cardiac tissue for 80+ years. 4. Magnification of Effect I think my thesis is likely correct that the effect will be magnified in humans. In mice, the study showed an 8% recovery in strength, a catastrophic failure. In a human heart, an 8% recovery rate after minor cellular stress or sub-clinical ischemia is essentially a death sentence or a fast-track to heart failure with preserved ejection fraction (HFpEF). 5. Heteroplasmy in the Myocardium Because the heart is post-mitotic (the cells don't divide often), it is uniquely susceptible to the heteroplasmy that I mentioned earlier. If the "repair signal" (PGE2) is degraded by the Gerozyme, and the GLP-1 drug is preventing stem cell activation, the human heart is forced to run on "broken engines" (damaged mitochondria) without the ability to replace them. Summary From My Thesis: I can now argue based on the Blau data that the "Ozempic face" (loss of facial fat/collagen) is just a visual precursor to "Ozempic heart," a state where the most vital muscle in the body is losing its regenerative capacity and accumulating mitochondrial mutations (heteroplasmy) faster than it can repair them. I bet this will get this will get this pre print retracted and this will never be in PEER reviewed literature. 6. Identifying a Specific Biological Mechanism The study suggests that semaglutide doesn't just "cause" muscle loss via weight loss; it appears to interact with the 15-PGDH (Gerozyme) pathway. The Problem: Ozempic alone seems to suppress muscle stem cell function (down to 20% in mice), effectively "locking" the repair mechanism. When you realize in humans BCL11A is tied to regeneration and also sits on Chromosome 2 in humans with the glucagon gene. This is a high-level genetic catch from my thesis. I'm pointing to a "hot spot" on Chromosome 2 (2p15-p16) where the Glucagon gene (GCG), the precursor to GLP-1, resides near BCL11A. The Link: BCL11A is famous for the "fetal-to-adult" hemoglobin switch, but recent research also ties it to regenerative capacity and cell fate. My Thesis Fit: If GLP-1 drugs over-stimulate pathways linked to this region, they might inadvertently trigger a "switch" that favors immediate metabolic stability over long-term regenerative "fetal-like" plasticity. This supports my idea of a fundamental "locking" of repair and dying early from these drugs. The Result: This leads to a failure in regeneration and strength recovery (dropping to 8% in the study), suggesting that users might not just be "thinner," but biologically "older" in terms of muscle resilience due to increased heteroplasmy. I said this in my thesis and now I have proof of it. 7. The "Gerozyme" Link By linking GLP-1s to the 15-PGDH enzyme, my thesis can bridge metabolic health with longevity science. If 15-PGDH degrades PGE2 (the repair signal), then GLP-1 drugs "inadvertently accelerate" a marker of aging in muscle tissue. Human studies have shown that 15-PGDH activity is elevated in aged cardiac tissue, leading to a localized drop in PGE2. Human Relevance: Microarray data from human biopsies shows that 15-PGDH expression increases significantly with age in cardiovascular tissues. The GLP-1 Interaction: If GLP-1 drugs further suppress the "repair signal" (PGE2) while this enzyme is already high, it creates a "perfect storm" for cardiac cell failure. In mice, inhibiting this enzyme reversed diastolic dysfunction and reduced Troponin I (a marker of heart damage). Without this "fix," the damage this is why I anticipate in humans the process is deadly. Fits with the Rockefeller eugenics plan (COVID jab). My point about the human heart's mitochondrial density is the "smoking gun for the death sentence these drugs are delivering to people today." Mitochondrial "Lock-out": 15-PGDH inhibition has been shown to restore mitochondrial morphology, turning "large, distended, vacuous" aged mitochondria into "round, compact, healthy" ones. The Human Penalty: Because humans have higher mitochondrial capacity requirements, the failure to repair these organelles (due to the GLP-1/Gerozyme interaction) will lead to accelerated heteroplasmy in the heart much faster than in the short-lived mouse. The known already published research indicates that 15-PGDH promotes cardiac fibrosis (scarring) via TGF-β1 signaling. My Thesis Fit: You can argue that the "weight loss" seen on GLP-1s hides a "stiffening" of the heart. While the patient looks "fit" due to the scale, their myocardium is accumulating fibrotic tissue because the PGE2 "anti-fibrotic" shield has been compromised. This means anyone on these drugs needs to have invasive caridac testing to see how the drug has already damaged their hearts. Sounds a lot like the COVID jab if you ask me (myocarditis risk). Comparison: Mouse vs. Human Cardiac Impact slide below. Dr. Williams is a danger to patients. The public should be aware he cannot read well, and not comprehend the implications of recent research.

More on this app are starting to notice this now But we have been talking about it for WEEKS 2022 fractal vs 2026 HTF hot zone We will know soon! Catch me in discord #Bitcoin

$BTC - Higher Timeframe Structure is still BEARISH! Back in early February I said that #Bitcoin was entering a tedious consolidation phase, likely to bounce around for months. Price is now sitting right in the middle of the 2024 structure. Personally, I’m not making any moves here. Anyone buying at these levels should understand it’s only a counter-trend trade and should be cautious. For now, I’m only interested in longs or shorts at the extremes of the range. Buying around 50k–56k could offer a decent bounce. But if price revisits the high 70s to mid-80s, I’ll be placing many short orders, because I still believe there’s more downside ahead. If we do bounce that high, it will likely be another liquidity grab by market makers, similar to what happened in January. Bulls will get excited, people will believe 60k was the bottom, those who didn’t buy will FOMO… and once again get dragged down. Predicting this short-term range hasn’t been easy, I must admit. But if there’s one thing I’m confident about, it’s my long-term analysis.